Q-omics provides the consensus-scored SP1 profile across patient tissues and cancer cell-line models. SP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SP1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SP1 protein abundance shows 22,223 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where SP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SP1 survival associations across molecular data types. SP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SP1 RNA expression–survival associations across cancer types. High SP1 expression shows unfavorable associations in ACC, PAAD, LIHC and LGG, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SP1 RNA expression.
This table summarizes SP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SP1 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, KIRP, STAD and CHOL. The KIRC box plot shows higher SP1 RNA expression in tumor versus normal tissue (log2 FC = +0.505, t-test p < 0.001).
This table shows molecular features associated with SP1 in patient tissues and cancer cell lines. In patient samples, SP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
